Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment and at Six Month Follow-up (11-196A)
Protocol ID
11-196A
Protocol Description
Many cancer patients report mild to moderate cognitive difficulties (such as problems remembering things, multi-tasking, or concentrating) during and following treatment of their cancer. Currently the cause of these difficulties is unknown and there aren’t any effective treatments.
This study is being conducted to better understand how common these cognitive difficulties are by using cognitive testing measures, as well as, self-report measures (surveys). It is believed that cognitive difficulties associated with cancer and chemotherapy treatments may be related to increased inflammation and other processes that can impact inflammation in the body. Inflammation and inflammation-related processes are associated with cognitive difficulties in other diseases, and the same may be true for cancer and cognition. This study will evaluate these relationships by assessing blood and DNA (DNA is the genetic information in the cells that is passed down from generation to generation in families).
Half of the participants in this study will be receiving chemotherapy and the other half will be controls of the same age and gender, who are not receiving chemotherapy. The control participants will be compared to the chemotherapy participants to try and determine if the cancer participants have cognitive difficulties that are better or worse than people without cancer.
Eligibility Criteria
• Healthy Controls that can speak and read English, or
• Participants must have a diagnosis of invasive breast cancer (stage I-IIIC) or intermediate or high-grade lymphoma, and
o be scheduled to begin a course of chemotherapy, and
o have not received chemotherapy in the past, and
o be able to speak and read English
• Participants must have a diagnosis of invasive breast cancer (stage I-IIIC) or intermediate or high-grade lymphoma, and
o be scheduled to begin a course of chemotherapy, and
o have not received chemotherapy in the past, and
o be able to speak and read English
Primary Investigator(s)
- Vincent Vinciguerra, MD